Neurofibromatosis 1–associated optic pathway gliomas



Optic Pathway Gliomas (OPG) are the most common brain tumor in Neurofibromatosis 1 patients (NF1). They are found along the optic pathway and may involve the optic nerves, chiasm, retro-chiasmatic structures, and the optic radiations. NF1 associate OPG (NF1-OPG) have variable presentation, disease course and response to treatment. The optimal management is patient-specific and should be tailored by a multidisciplinary team. Age, sex, histology, and molecular markers may be important factors in the individualized decision-making process. Chemotherapy is the first-line treatment in cases of progressive tumors, and visual preservation is the main goal of treatment.


In this paper we will review the disease, practical management, and recent advances of NF1-OPG.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4


  1. 1.

    Shamji MF, Benoit BG (2007) Syndromic and sporadic pediatric optic pathway gliomas: review of clinical and histopathological differences and treatment implications. Neurosurg Focus 23:E3

    Article  Google Scholar 

  2. 2.

    Nicolin G, Parkin P, Mabbott D, Hargrave D, Bartels U, Tabori U, Rutka J, Buncic JR, Bouffet E (2009) Natural history and outcome of optic pathway gliomas in children. Pediatr Blood Cancer 53:1231–1237.

    Article  Google Scholar 

  3. 3.

    Grill J, Laithier V, Rodriguez D et al (2000) When do children with optic pathway tumours need treatment? An oncological perspective in 106 patients treated in a single centre. Eur J Pediatr 159:692–696

    CAS  Article  Google Scholar 

  4. 4.

    Tow SL, Chandela S, Miller NR, Avellino AM (2003) Long-term outcome in children with gliomas of the anterior visual pathway. Pediatr Neurol 28:262–270

    Article  Google Scholar 

  5. 5.

    Thiagalingam S, Flaherty M, Billson F, North K (2004) Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 111:568–577

    Article  Google Scholar 

  6. 6.

    Listernick R, Ferner RE, Liu GT, Gutmann DH (2007) Optic pathway gliomas in neurofibromatosis-1: controversies and recommendations. Ann Neurol 61:189–198

    CAS  Article  Google Scholar 

  7. 7.

    Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, D’Agostino McGowan L, Liu GT (2014) Gender as a disease modifier in neurofibromatosis type 1 optic pathway glioma. Ann Neurol 75:799–800.

    Article  Google Scholar 

  8. 8.

    McClatchey AI (2007) Neurofibromatosis. Annu Rev Pathol 2:191–216.

    CAS  Article  Google Scholar 

  9. 9.

    Czyzyk E, Jozwiak S, Roszkowski M, Schwartz RA (2003) Optic pathway gliomas in children with and without neurofibromatosis 1. J Child Neurol 18:471–478

    Article  Google Scholar 

  10. 10.

    Blanchard G, Lafforgue M-P, Lion-François L, Kemlin I, Rodriguez D, Castelnau P, Carneiro M, Meyer P, Rivier F, Barbarot S, Chaix Y, NF France network (2016) Systematic MRI in NF1 children under six years of age for the diagnosis of optic pathway gliomas. Study and outcome of a French cohort. Eur J Paediatr Neurol 20:275–281.

    Article  Google Scholar 

  11. 11.

    Listernick R, Charrow J, Greenwald M, Mets M (1994) Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 125:63–66.

    CAS  Article  Google Scholar 

  12. 12.

    Blazo MA, Lewis RA, Chintagumpala MM, Frazier M, McCluggage C, Plon SE (2004) Outcomes of systematic screening for optic pathway tumors in children with neurofibromatosis type 1. Am J Med Genet A 127A:224–229.

    CAS  Article  Google Scholar 

  13. 13.

    Chateil JF, Soussotte C, Pedespan JM et al (2001) MRI and clinical differences between optic pathway tumours in children with and without neurofibromatosis. Br J Radiol 74:24–31

    CAS  Article  Google Scholar 

  14. 14.

    Hernaiz Driever P, von Hornstein S, Pietsch T et al (2010) Natural history and management of low-grade glioma in NF-1 children. J Neuro-Oncol 100:199–207.

    Article  Google Scholar 

  15. 15.

    Shofty B, Constantini S, Bokstein F, Ram Z, Ben-Sira L, Freedman S, Vainer G, Kesler A (2014) Optic pathway gliomas in adults. Neurosurgery 74:273–280.

    Article  Google Scholar 

  16. 16.

    Schindera C, Wingeier K, Goeggel Simonetti B, Diepold M, Nauer CB, Fleischhauer J, Steinlin M (2011) Macrocephaly in neurofibromatosis type 1: a sign post for optic pathway gliomas? Childs Nerv Syst 27:2107–2111.

    Article  Google Scholar 

  17. 17.

    Sharif S, Upadhyaya M, Ferner R, Majounie E, Shenton A, Baser M, Thakker N, Evans DG (2011) A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations. J Med Genet 48:256–260.

    CAS  Article  Google Scholar 

  18. 18.

    Hutter S, Piro RM, Waszak SM, Kehrer-Sawatzki H, Friedrich RE, Lassaletta A, Witt O, Korbel JO, Lichter P, Schuhmann MU, Pfister SM, Tabori U, Mautner VF, Jones DTW (2016) No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients. Hum Genet 135:469–475.

    CAS  Article  Google Scholar 

  19. 19.

    Ahn Y, Cho BK, Kim SK, Chung YN, Lee CS, Kim IH, Yang SW, Kim HS, Kim HJ, Jung HW, Wang KC (2006) Optic pathway glioma: outcome and prognostic factors in a surgical series. Childs Nerv Syst 22:1136–1142

    Article  Google Scholar 

  20. 20.

    Lee AG (2007) Neuroophthalmological management of optic pathway gliomas. Neurosurg Focus 23:E1

    Article  Google Scholar 

  21. 21.

    Shofty B, Ben-Sira L, Freedman S, Yalon M, Dvir R, Weintraub M, Toledano H, Constantini S, Kesler A (2011) Visual outcome following chemotherapy for progressive optic pathway gliomas. Pediatr Blood Cancer 57:481–485.

    Article  Google Scholar 

  22. 22.

    Allen JC (2000) Initial management of children with hypothalamic and thalamic tumors and the modifying role of neurofibromatosis-1. Pediatr Neurosurg 32:154–162.

    CAS  Article  Google Scholar 

  23. 23.

    Dodge HW (1958) Gliomas of the optic nerves. AMA Arch Neur Psychiatry 79:607–621.

    Article  Google Scholar 

  24. 24.

    Taylor T, Jaspan T, Milano G, Gregson R, Parker T, Ritzmann T, Benson C, Walker D, PLAN Study Group (2008) Radiological classification of optic pathway gliomas: experience of a modified functional classification system. Br J Radiol 81:761–766.

    CAS  Article  Google Scholar 

  25. 25.

    McCullough DC, Epstein F (1985) Optic pathway tumors. A review with proposals for clinical staging. Cancer 56:1789–1791.<1789::aid-cncr2820561312>;2-y

    CAS  Article  Google Scholar 

  26. 26.

    Shofty B, Weizman L, Joskowicz L, Constantini S, Kesler A, Ben-Bashat D, Yalon M, Dvir R, Freedman S, Roth J, Ben-Sira L (2011) MRI internal segmentation of optic pathway gliomas: clinical implementation of a novel algorithm. Childs Nerv Syst 27:1265–1272.

    Article  Google Scholar 

  27. 27.

    Shofty B, Mauda-Havakuk M, Weizman L, Constantini S, Ben-Bashat D, Dvir R, Pratt LT, Joskowicz L, Kesler A, Yalon M, Ravid L, Ben-Sira L (2015) The effect of chemotherapy on optic pathway gliomas and their sub-components: a volumetric MR analysis study. Pediatr Blood Cancer 62:1353–1359.

    CAS  Article  Google Scholar 

  28. 28.

    Weizman L, Ben Sira L, Joskowicz L, Constantini S, Precel R, Shofty B, Ben Bashat D (2012) Automatic segmentation, internal classification, and follow-up of optic pathway gliomas in MRI. Med Image Anal 16:177–188.

    CAS  Article  Google Scholar 

  29. 29.

    Hollander MD, FitzPatrick M, O’Connor SG et al (1999) Optic gliomas. Radiol Clin N Am 37(59–71):ix–71.

    Article  Google Scholar 

  30. 30.

    Peyster RG, Hoover ED, Hershey BL, Haskin ME (1983) High-resolution CT of lesions of the optic nerve. AJR Am J Roentgenol 140:869–874.

    CAS  Article  Google Scholar 

  31. 31.

    Shofty B, Ben-Sira L, Constantini S, Freedman S, Kesler A (2012) Optic nerve sheath diameter on MR imaging: establishment of norms and comparison of pediatric patients with idiopathic intracranial hypertension with healthy controls. Am J Neuroradiol 33:366–369.

    CAS  Article  Google Scholar 

  32. 32.

    Lober RM, Guzman R, Cheshier SH, Fredrick DR, Edwards MSB, Yeom KW (2012) Application of diffusion tensor tractography in pediatric optic pathway glioma. J Neurosurg Pediatr 10:273–280.

    Article  Google Scholar 

  33. 33.

    Filippi CG, Bos A, Nickerson JP, Salmela MB, Koski CJ, Cauley KA (2012) Magnetic resonance diffusion tensor imaging (MRDTI) of the optic nerve and optic radiations at 3T in children with neurofibromatosis type I (NF-1). Pediatr Radiol 42:168–174.

    Article  Google Scholar 

  34. 34.

    de Blank PM, Berman JI, Liu GT et al (2013) Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1. Neuro-oncology 15:1088–1095.

    CAS  Article  Google Scholar 

  35. 35.

    Weizman L, Joskowicz L, Ben-Sira L, et al (2011) Longitudinal assessment of brain tumors using a repeatable prior-based segmentation. In: Proceedings - International Symposium on Biomedical Imaging

  36. 36.

    Avery RA, Bouffet E, Packer RJ, Reginald A (2013) Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas. Invest Ophthalmol Vis Sci 54:1034–1038.

    Article  Google Scholar 

  37. 37.

    Chang L, El-Dairi MA, Frempong TA et al (2010) Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas. J AAPOS 14:511–517.

    Article  Google Scholar 

  38. 38.

    Avery RA, Liu GT, Fisher MJ et al (2011) Retinal nerve fiber layer thickness in children with optic pathway gliomas. Am J Ophthalmol 151:542–549.e2.

    Article  Google Scholar 

  39. 39.

    Taylor M, Couto-Silva A-C, Adan L, Trivin C, Sainte-Rose C, Zerah M, Valteau-Couanet D, Doz F, Chalumeau M, Brauner R (2012) Hypothalamic-pituitary lesions in pediatric patients: endocrine symptoms often precede neuro-ophthalmic presenting symptoms. J Pediatr 161:855–863.

    Article  Google Scholar 

  40. 40.

    Cnossen MH, Stam EN, Cooiman LC et al (1997) Endocrinologic disorders and optic pathway gliomas in children with neurofibromatosis type 1. Pediatrics 100:667–670

    CAS  Article  Google Scholar 

  41. 41.

    Komotar RJ, Burger PC, Carson BS, Brem H, Olivi A, Goldthwaite PT, Tihan T (2004) Pilocytic and pilomyxoid hypothalamic/chiasmatic astrocytomas. Neurosurgery 54:72–79; discussion 79-80.

    Article  Google Scholar 

  42. 42.

    Amatya VJ, Akazawa R, Sumimoto Y, Takeshima Y, Inai K (2009) Clinicopathological and immunohistochemical features of three pilomyxoid astrocytomas: comparative study with 11 pilocytic astrocytomas. Pathol Int 59:80–85.

    Article  Google Scholar 

  43. 43.

    Zoeller GK, Brathwaite CD, Sandberg DI (2010) Malignant transformation of an optic pathway glioma without prior radiation therapy. J Neurosurg Pediatr 5:507–510.

    Article  Google Scholar 

  44. 44.

    Piccirilli M, Lenzi J, Delfinis C, Trasimeni G, Salvati M, Raco A (2006) Spontaneous regression of optic pathways gliomas in three patients with neurofibromatosis type I and critical review of the literature. Childs Nerv Syst 22:1332–1337

    Article  Google Scholar 

  45. 45.

    Rozen WM, Joseph S, Lo PA (2008) Spontaneous regression of low-grade gliomas in pediatric patients without neurofibromatosis. Pediatr Neurosurg 44:324–328.

    Article  Google Scholar 

  46. 46.

    King A, Listernick R, Charrow J et al (2003) Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome. Am J Med Genet A 122:95–99

    Article  Google Scholar 

  47. 47.

    Kinori M, Armarnik S, Listernick R, Charrow J, Zeid JL (2020) Neurofibromatosis type 1 associated optic pathway glioma in children - a follow up of 10 years or more. Am J Ophthalmol.

  48. 48.

    Gajjar A, Bhargava R, Jenkins JJ, Heideman R, Sanford RA, Langston JW, Walter AW, Kuttesch JF, Muhlbauer M, Kun LE (1995) Low-grade astrocytoma with neuraxis dissemination at diagnosis. J Neurosurg 83:67–71.

    CAS  Article  Google Scholar 

  49. 49.

    Hawkins C, Walker E, Mohamed N, Zhang C, Jacob K, Shirinian M, Alon N, Kahn D, Fried I, Scheinemann K, Tsangaris E, Dirks P, Tressler R, Bouffet E, Jabado N, Tabori U (2011) BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res 17:4790–4798.

    CAS  Article  Google Scholar 

  50. 50.

    Astrup J (2003) Natural history and clinical management of optic pathway glioma. Br J Neurosurg 17:327–335.

    CAS  Article  Google Scholar 

  51. 51.

    Fouladi M, Wallace D, Langston JW, Mulhern R, Rose SR, Gajjar A, Sanford RA, Merchant TE, Jenkins JJ, Kun LE, Heideman RL (2003) Survival and functional outcome of children with hypothalamic/chiasmatic tumors. Cancer 97:1084–1092.

    Article  Google Scholar 

  52. 52.

    Shofty B, Ben-Sira L, Kesler A, Constantini S (2015) Optic pathway gliomas. In: Advances and technical standards in neurosurgery. pp 123–146

  53. 53.

    Walker DA, Liu J, Kieran M, Jabado N, Picton S, Packer R, St. Rose C, (on behalf of the CPN Paris 2011 Conference Consensus Group), van Meeteren AS, Carvalho A, van Damme A, Depreitere B, Gustavsson B, Due Tonnessen BJ, Bertozzi-Salamon AI, Brentrup A, Raybaud C, Jones C, Dufour C, Dorfer C, Sainte-Rose C, Malluci C, Hargrave D, Walker D, van Vuurden D, de Carli E, Bouffet E, van Calenbergh F, Frappaz D, Frassanito P, Goodrich J, Baechli H, Grill J, Ternier J, Cappelen J, Caird J, Pereira J, Riffaud L, Baroncini M, Walker M, Kieran M, Ozek M, Jabado N, Nysom K, Varlet P, Goodden J, Bertolini P, Perilongo G, Mercier P, Grundy R, Kortmann RD, Packer R, Pfister S, Constantini S, Sgouros S, Holm S, Czech T, Merchant T, Stokland T, Ridola V, Vandertop P (2013) A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro-oncology 15:462–468.

    Article  Google Scholar 

  54. 54.

    Packer RJ, Ater J, Allen J, Phillips P, Geyer R, Nicholson HS, Jakacki R, Kurczynski E, Needle M, Finlay J, Reaman G, Boyett JM (1997) Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 86:747–754.

    CAS  Article  Google Scholar 

  55. 55.

    Aquino VM, Fort DW, Kamen BA (1999) Carboplatin for the treatment of children with newly diagnosed optic chiasm gliomas: a phase II study. J Neuro-Oncol 41:255–259.

    CAS  Article  Google Scholar 

  56. 56.

    Lafay-Cousin L, Holm S, Qaddoumi I, Nicolin G, Bartels U, Tabori U, Huang A, Bouffet E (2005) Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer 103:2636–2642.

    CAS  Article  Google Scholar 

  57. 57.

    Gururangan S, Fisher MJ, Allen JC et al (2007) Temozolomide in children with progressive low-grade glioma. Neuro-oncol 9:161–168.

    CAS  Article  Google Scholar 

  58. 58.

    Ryall S, Zapotocky M, Fukuoka K et al (2020) Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 37:569–583.e5.

    CAS  Article  Google Scholar 

  59. 59.

    Ullrich NJ, Prabhu SP, Reddy AT, Fisher MJ, Packer R, Goldman S, Robison NJ, Gutmann DH, Viskochil DH, Allen JC, Korf B, Cantor A, Cutter G, Thomas C, Perentesis JP, Mizuno T, Vinks AA, Manley PE, Chi SN, Kieran MW (2020) A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a neurofibromatosis clinical trials consortium study. Neuro-oncol.

  60. 60.

    Yalon M, Rood B, MacDonald TJ et al (2013) A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG). Pediatr Blood Cancer 60:71–76.

    CAS  Article  Google Scholar 

  61. 61.

    Klesse LJ, Jordan JT, Radtke HB, Rosser T, Schorry E, Ullrich N, Viskochil D, Knight P, Plotkin SR, Yohay K (2020) The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities. Oncologist.

  62. 62.

    Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH, Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS, Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS, Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ, Fouladi M (2019) Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 20:1011–1022.

    CAS  Article  Google Scholar 

  63. 63.

    Campagna M, Opocher E, Viscardi E, Calderone M, Severino SM, Cermakova I, Perilongo G (2010) Optic pathway glioma: long-term visual outcome in children without neurofibromatosis type-1. Pediatr Blood Cancer 55:1083–1088.

    Article  Google Scholar 

  64. 64.

    Fisher MJ, Balcer L, Gutmann DH et al (2010) Neurofibromatosis type I associated optic glioma visual outcomes following chemotherapy: an international multi-center retrospective analysis. Neuro-oncol 12:ii19–ii20

    Article  Google Scholar 

  65. 65.

    Leonard JR, Perry A, Rubin JB et al (2006) The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology 67:1509–1512.

    CAS  Article  Google Scholar 

  66. 66.

    Gnekow AK, Kandels D, van Tilburg C et al (2019) SIOP-E-BTG and GPOH guidelines for diagnosis and treatment of children and adolescents with low grade glioma. Klin Padiatr 231:107–135.

    Article  Google Scholar 

  67. 67.

    Shofty B, Ben-Sira L, Kesler A, Jallo G, Groves ML, Iyer RR, Lassaletta A, Tabori U, Bouffet E, Thomale UW, Hernáiz Driever P, Constantini S et al (2017) Isolated optic nerve gliomas: a multicenter historical cohort study. J Neurosurg Pediatr 20.

  68. 68.

    Wisoff JH, Abbott R, Epstein F (1990) Surgical management of exophytic chiasmatic-hypothalamic tumors of childhood. J Neurosurg 73:661–667.

    CAS  Article  Google Scholar 

  69. 69.

    Fisher BJ, Leighton CC, Vujovic O, Macdonald DR, Stitt L (2001) Results of a policy of surveillance alone after surgical management of pediatric low grade gliomas. Int J Radiat Oncol Biol Phys 51:704–710.

    CAS  Article  Google Scholar 

  70. 70.

    Steinbok P, Hentschel S, Almqvist P, Cochrane DD, Poskitt K (2002) Management of optic chiasmatic/hypothalamic astrocytomas in children. Can J Neurol Sci 29:132–138

    Article  Google Scholar 

  71. 71.

    Hoffman HJ, Soloniuk DS, Humphreys RP, Drake JM, Becker LE, de Lima BO, Piatt JH Jr (1993) Management and outcome of low-grade astrocytomas of the midline in children: a retrospective review. Neurosurgery 33:964–971.

    CAS  Article  Google Scholar 

  72. 72.

    Goodden J, Pizer B, Pettorini B, Williams D, Blair J, Didi M, Thorp N, Mallucci C (2014) The role of surgery in optic pathway/hypothalamic gliomas in children. J Neurosurg Pediatr 13:1–12.

    Article  Google Scholar 

  73. 73.

    Sawamura Y, Kamada K, Kamoshima Y, Yamaguchi S, Tajima T, Tsubaki J, Fujimaki T (2008) Role of surgery for optic pathway/hypothalamic astrocytomas in children. Neuro-oncol 10:725–733.

    Article  Google Scholar 

  74. 74.

    Hidalgo ET, Kvint S, Orillac C, North E, Dastagirzada Y, Chang JC, Addae G, Jennings TS, Snuderl M, Wisoff JH (2019) Long-term clinical and visual outcomes after surgical resection of pediatric pilocytic/pilomyxoid optic pathway gliomas. J Neurosurg Pediatr 24:1–8.

    Article  Google Scholar 

  75. 75.

    Millward CP, Perez Da Rosa S, Avula S et al (2015) The role of early intra-operative MRI in partial resection of optic pathway/hypothalamic gliomas in children. Childs Nerv Syst 31:2055–2062.

    Article  Google Scholar 

  76. 76.

    van Baarsen K, Roth J, Serova N, Packer RJ, Shofty B, Thomale UW, Cinalli G, Toledano H, Michowiz S, Constantini S (2018) Optic pathway-hypothalamic glioma hemorrhage: a series of 9 patients and review of the literature. J Neurosurg 129:1407–1415.

    Article  Google Scholar 

  77. 77.

    Gil Z, Beni-Adani L, Siomin V, Nagar H, Dvir R, Constantini S (2001) Ascites following ventriculoperitoneal shunting in children with chiasmatic-hypothalamic glioma. Childs Nerv Syst 17:395–398.

    CAS  Article  Google Scholar 

  78. 78.

    Merchant TE, Conklin HM, Wu S, Lustig RH, Xiong X (2009) Late effects of conformal radiation therapy for pediatric patients with low-grade glioma: prospective evaluation of cognitive, endocrine, and hearing deficits. J Clin Oncol 27:3691–3697.

    Article  Google Scholar 

  79. 79.

    Tsang DS, Murphy ES, Merchant TE (2017) Radiation therapy for optic pathway and hypothalamic low-grade gliomas in children. Int J Radiat Oncol Biol Phys 99:642–651.

    Article  Google Scholar 

  80. 80.

    Ullrich NJ, Robertson R, Kinnamon DD, Scott RM, Kieran MW, Turner CD, Chi SN, Goumnerova L, Proctor M, Tarbell NJ, Marcus KJ, Pomeroy SL (2007) Moyamoya following cranial irradiation for primary brain tumors in children. Neurology 68:932–938.

    CAS  Article  Google Scholar 

  81. 81.

    Jenkin D, Angyalfi S, Becker L, Berry M, Buncic R, Chan H, Doherty M, Drake J, Greenberg M, Hendrick B, Hoffman H, Humphreys R, Weitzman S (1993) Optic glioma in children: surveillance, resection, or irradiation? Int J Radiat Oncol Biol Phys 25:215–225.

    CAS  Article  Google Scholar 

  82. 82.

    Opocher E, Kremer LC, Da Dalt L et al (2006) Prognostic factors for progression of childhood optic pathway glioma: a systematic review. Eur J Cancer 42:1807–1816

    Article  Google Scholar 

  83. 83.

    Fisher MJ, Avery RA, Allen JC, Ardern-Holmes SL, Bilaniuk LT, Ferner RE, Gutmann DH, Listernick R, Martin S, Ullrich NJ, Liu GT, For the REiNS International Collaboration (2013) Functional outcome measures for NF1-associated optic pathway glioma clinical trials. Neurology 81:S15–S24.

    CAS  Article  Google Scholar 

  84. 84.

    Gayre GS, Scott IU, Feuer W, Saunders TG, Siatkowski RM (2001) Long-term visual outcome in patients with anterior visual pathway gliomas. J Neuroophthalmol 21:1–7

    CAS  Article  Google Scholar 

  85. 85.

    Dalla Via P, Opocher E, Pinello ML, Calderone M, Viscardi E, Clementi M, Battistella PA, Laverda AM, da Dalt L, Perilongo G (2007) Visual outcome of a cohort of children with neurofibromatosis type 1 and optic pathway glioma followed by a pediatric neuro-oncology program. Neuro-oncol 9:430–437

    Article  Google Scholar 

  86. 86.

    Moreno L, Bautista F, Ashley S, Duncan C, Zacharoulis S (2010) Does chemotherapy affect the visual outcome in children with optic pathway glioma? A systematic review of the evidence. Eur J Cancer S0959-8049(10):00259–00255.

    Article  Google Scholar 

  87. 87.

    Sharif S, Ferner R, Birch JM et al (2006) Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 24:2570–2575.

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Shlomi Constantini.

Ethics declarations

Conflict of interest

All authors declare no conflict of interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Shofty, B., Ben Sira, L. & Constantini, S. Neurofibromatosis 1–associated optic pathway gliomas. Childs Nerv Syst (2020).

Download citation


  • Optic pathway glioma
  • OPG
  • Neurofibromatosis 1
  • NF1
  • Low-grade glioma
  • Chemotherapy
  • Radiotherapy
  • Neurosurgery